drugset / Trial / NCT04475731
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in the few patients who never achieved an hematologic remission after whatever prior treatment.
Timeline
- Start
- 2021-05-04
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponatinib | Small molecule | 45 mg | Oral |
| Background | Cytarabine | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Vincristine | Small molecule | — | — |